LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
21 hedge funds and large institutions have $16.1M invested in LAVA Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 6 closing their positions.
160% more call options, than puts
Call options by funds: $226K | Put options by funds: $87K
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
52% more capital invested
Capital invested by funds: $10.6M → $16.1M (+$5.48M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
11% more funds holding
Funds holding: 19 → 21 (+2)
8.64% more ownership
Funds ownership: 30.61% → 39.25% (+8.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$3.81M |
| 2 |
GS
GTS Securities
New York
|
+$299K |
| 3 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$206K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$66.2K |
| 5 |
JC
JBF Capital
Aspen,
Colorado
|
+$35.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
-$689K |
| 2 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
-$135K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$61.9K |
| 4 |
Two Sigma Investments
New York
|
-$45.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$18.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$18.8K | -14,236 | Closed |
|
27
Morgan Stanley
New York
| – | -$15.3K | -11,600 | Closed |
|
LVTX Hedge Fund Activity: Q3 2025 in Review
21 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q3 2025, worth a combined $16.1M — up 52% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LVTX positions and 6 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Shay Capital, opening a new position worth an estimated $3.81M. The largest seller was Bruce & Co, exiting entirely with an estimated $689K sold.
- 21 institutional investors held LAVA Therapeutics (LVTX) as of Q3 2025, up from 19 in Q2 2025.
- Funds reported $16.1M of LAVA Therapeutics stock for Q3 2025, up 52% quarter-over-quarter.
- 8 funds opened new LAVA Therapeutics positions in Q3 2025 and 6 closed out, a net change of +2 holders.
- The largest LAVA Therapeutics buyer in Q3 2025 was Shay Capital, an estimated $3.81M added.
- The largest LAVA Therapeutics seller in Q3 2025 was Bruce & Co, an estimated $689K sold.
Based on aggregated 13F filings for Q3 2025.